Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

Official Title

A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Keywords

Lymphoma, Follicular, Follicular lymphoma, Grade 1-3a Follicular lymphoma, BMS-986369, CC-99282, Lymphoma, golcadomide, Prednisone, Cyclophosphamide, Bendamustine Hydrochloride, Rituximab, Doxorubicin, Liposomal doxorubicin, Vincristine, Bendamustine, Rituximab + Chemotherapy

Eligibility

Locations

  • UCSF Helen Diller Medical Center at Parnassus Heights accepting new patients
    San Francisco California 94143 United States
  • Comprehensive Cancer Centers Of Nevada accepting new patients
    Henderson Nevada 89074 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Celgene
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
ID
NCT06425302
Phase
Phase 2 Lymphoma Research Study
Study Type
Interventional
Participants
Expecting 90 study participants
Last Updated